Treatment Algorithms: Prostate Cancer

Androgen deprivation therapy (ADT) is the standard of care for hormone-sensitive disease. Gonadotrophin hormone releasing hormone (GnRH) analogues leuprolide and goserelin co-administered with anti-androgens such as bicalutamide is the most common treatment regimen for achieving castrate levels of testosterone.

Features and benefits

• In-depth analysis of physician prescribing habits by disease stage across the seven major markets.
• In-depth analysis of most common treatment types according to stage at diagnosis and patient specifics.
• Analysis of patient advocacy and its influence on diagnosis rates.
• Insight into country-specific drug uptake by patient number, volume, and/or sales data.

Highlights

Prostate cancer is one of the ‘big four’ tumor types (along with breast cancer, lung cancer and colorectal cancer), and is the second most common cancer in males. Datamonitor estimates that 532,900 men were diagnosed with prostate cancer in the seven major markets (the US, Japan, France, Germany, Italy, Spain and the UK) in 2011 alone

The overall 5-year relative survival of prostate cancer patients is approximately 99.4%. The 10 and 15-year survival rates are approximately 93% and 77% respectively, although stage at diagnosis influences overall prognosis.

Physicians must take administration route, overall survival, and progression-free survival benefits as well as cost into consideration when deciding between use of Zytiga (abiraterone; Johnson&Johnson), Jevtana (cabazitaxel; Sanofi) and Provenge (sipuleucel-T; Dendreon).

Your key questions answered

• Understand how the dynamics of prostate cancer treatment are changing as a result of three recent drug approvals
• Analyze country, treatment and drug specific prescribing rates of prostate cancer drugs across the seven major markets
• Gain insight into the percentage of patients receiving new therapies gauging perspective into potential population sizes for pipeline drugs.